A bibliometric analysis of the 100 most influential papers on COPD

Figures & data

Table 1 The 100 most cited papers in COPD

Rank	First author	No of citations	Publication year	Citations/year	New rank*	Rank	First author	No of citations	Publication year	Citations/year	New rank*	Rank	First author	No of citations	Publication year	Citations/year	Newrank*
1	Rabe KF^Citation24	2,164	2007	270.50	1	35	Gosselink R^Citation66	407	1996	21.42	62	69	Barnes PJ^Citation99	303	2009	50.50	14
2	Celli BR^Citation25	1,659	2004	150.82	2	36	Seemungal T^Citation67	400	2001	28.57	46	70	Jones PW^Citation100	303	1997	16.83	80
3	Hogg JC^Citation26	1,246	2004	113.27	4	37	Ito K^Citation68	394	2005	39.40	25	71	Montuschi P^Citation101	301	2000	20.07	67
4	Celli BR^Citation35	1,177	2004	107.00	5	38	Szafranski W^Citation69	394	2003	32.83	35	72	Mahler DA^Citation102	297	1999	18.56	75
5	Calverley PMA^Citation36	1,146	2007	143.25	3	39	Saetta M^Citation70	383	1998	22.53	60	73	Nava S^Citation103	297	1998	17.47	78
6	Anthonisen NR^Citation37	1,129	1987	40.32	23	40	Anthonisen NR^Citation71	383	1986	13.21	93	74	Cazzola M^Citation104	296	2008	42.29	20
7	Siafakas NM^Citation38	1,006	1995	50.30	15	41	Hogg JC^Citation72	379	2004	34.45	33	75	Monso E^Citation105	293	1995	14.65	87
8	Brochard L^Citation39	834	1995	41.70	21	42	Landbo C^Citation73	379	1999	23.69	58	76	Renzetti AD^Citation106	292	1966	5.96	100
9	Keatings VM^Citation40	791	1996	41.63	22	43	Soler-Cataluna JJ^Citation74	373	2005	37.30	28	77	Maltais F^Citation107	289	1996	15.21	83
10	Seemungal TAR^Citation41	768	1998	45.18	17	44	Kuwano K^Citation75	372	1993	16.91	79	78	Wilson DO^Citation108	289	1989	11.12	95
11	Burge PS^Citation42	765	2000	51.00	12	45	Hurst JR^Citation27	367	2010	73.40	7	79	Seneff MG^Citation109	285	1995	14.25	90
12	Tashkin DP^Citation43	669	2008	95.57	6	46	Lacasse Y^Citation76	366	1996	19.26	72	80	Scanlon PD^Citation110	284	2000	18.93	74
13	Donaldson GC^Citation44	663	2002	51.00	13	47	Saint S^Citation77	366	1995	18.30	77	81	Paggiaro PL^Citation111	283	1998	16.65	81
14	Barnes PJ^Citation45	654	2000	43.60	19	48	Barnes PJ^Citation78	359	2008	51.29	11	82	Celli BR^Citation112	282	2008	40.29	24
15	Gan WQ^Citation46	597	2004	54.27	10	49	Niewoehner DE^Citation79	358	1999	22.38	61	83	Vestbo J^Citation113	279	1996	14.68	86
16	Barnes PJ^Citation47	556	2003	46.33	16	50	Bernard S^Citation80	358	1998	21.06	64	84	Papi A^Citation114	277	2006	30.78	42
17	Cooper JD^Citation48	555	1995	27.75	50	51	Bourbeau J^Citation81	357	2003	29.75	44	85	Saetta M^Citation115	277	2001	19.79	69
18	Calverley P^Citation49	540	2003	45.00	18	52	O’Donnell DE^Citation82	354	2004	32.18	38	86	Difrancia M^Citation116	277	1994	13.19	94
19	Bestall JC^Citation50	518	1999	32.38	36	53	Pitta F^Citation83	347	2005	34.70	32	87	Schols A^Citation117	275	1996	14.47	88
20	Buist AS^Citation51	510	2007	63.75	8	54	Keatings VM^Citation84	346	1997	19.22	73	88	Rahman I^Citation118	274	2006	30.44	43
21	Pauwels RA^Citation52	501	1999	31.31	39	55	O’Donnell DE^Citation85	344	2001	24.57	56	89	Sethi S^Citation119	272	2001	19.43	71
22	Schols A^Citation53	484	1998	28.47	48	56	Wiggs BR^Citation86	343	1992	14.91	84	90	Wedzicha JA^Citation120	268	2008	38.29	26
23	Ries AL^Citation54	482	1995	24.10	57	57	Pauwels RA^Citation87	342	2004	31.09	41	91	Dekhuijzen PNR^Citation121	267	1996	14.05	91
24	Repine JE^Citation55	457	1997	25.39	55	58	Halbert RJ^Citation88	337	2006	37.44	27	92	Donohue JF^Citation122	266	2002	20.46	65
25	Casaburi R^Citation56	456	2002	35.08	30	59	Murphy TF^Citation89	331	1992	14.39	89	93	Nishimura K^Citation123	263	2002	20.23	66
26	Mannino DM^Citation57	440	2007	55.00	9	60	McSweeny AJ^Citation90	329	1982	9.97	96	94	Menezes AMB^Citation124	262	2005	26.20	52
27	Rahman I^Citation58	432	1996	22.74	59	61	Schols A^Citation91	327	1993	14.86	85	95	Patel IS^Citation125	259	2002	19.92	68
28	Sethi S^Citation59	431	2002	33.15	34	62	Calverley PM^Citation92	326	2003	27.17	51	96	O’Donnell DE^Citation126	259	1998	15.24	82
29	Plant PK^Citation60	430	2000	28.67	45	63	Bhowmik A^Citation93	321	2000	21.40	63	97	Aaron SD^Citation127	258	2007	32.25	37
30	Sin DD^Citation61	428	2003	35.67	29	64	Lopez AD^Citation94	314	2006	34.89	31	98	Weitzenblum E^Citation128	258	1981	7.59	99
31	Seemungal T^Citation62	428	2000	28.53	47	65	Agusti AGN^Citation95	309	2003	25.75	54	99	Kanner RE^Citation129	257	2001	18.36	76
32	Altose MD^Citation63	422	2000	28.13	49	66	Traver GA^Citation96	308	1979	8.56	97	100	Marquis K^Citation28	254	2002	19.54	70
33	Vestbo J^Citation64	414	1999	25.88	53	67	Lambert RK^Citation97	304	1993	13.82	92
34	Vincken W^Citation65	407	2002	31.31	40	68	Wagner PD^Citation98	304	1977	8.00	98

Note:

* The “new rank” was sorted by the average annual number of citations.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Table 2 Top-ten sources that contribute most articles to the top-100 papers

Journal	Number
American Journal of Respiratory and Critical Care Medicine (Am J Respir Crit Care Med)	30
European Respiratory Journal (Eur Respir J)	14
New England Journal of Medicine (N Engl J Med)	12
Lancet	10
Thorax	8
American Review of Respiratory Disease (Am Rev Respir Dis)	7
Annals of Internal Medicine (Ann Intern Med)	4
Chest	3
Archives of Internal Medicine (Arch Intern Med)	2
Journal of the American Medical Association (J Am Med Assoc)	2

Table 3 Decades distribution of the top-100 most cited papers

Year	Number	Mean number of citations	Minimum number of citations	Maximum number of citations
−1980s	8	412	258	1,129
1990s	37	413	259	1,006
2000s	55	481	254	2,164

Table 4 Countries that contributed more than four papers in the 100 most influential papers

Country	Number
USA	38
England	34
Canada	20
Netherlands	12
Italy	10
Belgium	9
Spain	8
Denmark	7
Australia	6
Scotland	5

Table 5 The top-ten institutions contributing to the most cited articles in COPD

Institute	Number
Imperial College London	16
University of London	10
GlaxoSmithKline	9
St Georges University London	8
University of British Columbia	8
University of California System	8
Oregon Health Science University	7
Oregon University System	7
Queen Mary University London	7
University of Copenhagen	7

Abbreviation: COPD, chronic obstructive pulmonary disease.

Table 6 Research field of the most cited articles in COPD

Field	Number
General internal medicine	63
Respiratory system	63
Cardiovascular system cardiology	2
Immunology	1
Microbiology	1
Physiology	1
Research experimental medicine	1
Sport sciences	1
Surgery	1

Abbreviation: COPD, chronic obstructive pulmonary disease.

Table 7 The authors who contribute more than four articles to the top-100 papers

Author	Number of citation classics	Position on author list
Barnes PJ^Citation24,Citation40,Citation45,Citation47,Citation68,Citation78,Citation84,Citation99,Citation101,Citation104	10	First author – 4, fourth – 3, sixth – 1, seventh – 1, others – 1
Wedzicha JA^Citation27,Citation41,Citation44,Citation50,Citation62,Citation67,Citation93,Citation104,Citation120,Citation125	10	First author – 1, fourth – 2, fifth – 1, sixth – 3, others – 3
Vestbo J^Citation25,Citation27,Citation36,Citation49,Citation64,Citation73,Citation112,Citation113	8	First author – 2, second – 1, third – 1, fourth – 1, sixth – 1, eighth – 1, others – 1
Jones PW^Citation36,Citation42,Citation49,Citation50,Citation56,Citation100,Citation104	7	First author – 1, third – 2, fifth – 1, sixth – 2, others – 1
Buist AS^Citation24,Citation25,Citation51,Citation57,Citation88,Citation110	6	First author – 1, second – 1, fifth – 1, sixth – 2, others – 1
Calverley PMA^Citation24,Citation36,Citation42,Citation49,Citation92,Citation120	6	First author – 1, second – 2, seventh – 1, ninth – 1, tenth – 1
Hogg JC^Citation26,Citation68,Citation72,Citation75,Citation86,Citation97	6	First author – 2, fourth – 1, fifth – 1, sixth – 1, tenth – 1
Anthonisen NR^Citation37,Citation63,Citation71,Citation108,Citation129	5	First author – 2, second – 1, fourth – 1, others – 1
Celli BR^Citation25,Citation35,Citation36,Citation99,Citation112	5	First author – 3, second – 1, tenth – 1
Maltais F^Citation28,Citation80,Citation81,Citation107,Citation127	5	First author – 1, third – 1, fourth – 1, seventh – 2
Seemungal TAR^Citation41,Citation44,Citation93,Citation120,Citation125	5	First author – 2, second – 3

RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2007176653255517507545

 PubMed Web of Science ®Google Scholar

GosselinkRTroostersTDecramerMPeripheral muscle weakness contributes to exercise limitation in COPDAm J Respir Crit Care Med199615339769808630582

 PubMed Web of Science ®Google Scholar

BarnesPJCelliBRSystemic manifestations and comorbidities of COPDEur Respir J20093351165118519407051

 PubMed Web of Science ®Google Scholar

CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010

 PubMed Web of Science ®Google Scholar

SeemungalTHarper-OwenRBhowmikARespiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116491618162311719299

 PubMed Web of Science ®Google Scholar

JonesPWBoshTKQuality of life changes in COPD patients treated with salmeterolAm J Respir Crit Care Med19971554128312899105068

 PubMed Web of Science ®Google Scholar

HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480

 PubMed Web of Science ®Google Scholar

ItoKItoMElliottWMDecreased histone deacetylase activity in chronic obstructive pulmonary diseaseN Engl J Med2005352191967197615888697

 PubMed Web of Science ®Google Scholar

MontuschiPCollinsJVCiabattoniGExhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokersAm J Respir Crit Care Med20001623 Pt 11175117710988150

 PubMed Web of Science ®Google Scholar

CelliBRCoteCGMarinJMThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med2004350101005101214999112

 PubMed Web of Science ®Google Scholar

SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112

 PubMed Web of Science ®Google Scholar

MahlerDADonohueJFBarbeeRAEfficacy of salmeterol xinafoate in the treatment of COPDChest1999115495796510208192

 PubMed Web of Science ®Google Scholar

CalverleyPMAAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337

 PubMed Web of Science ®Google Scholar

SaettaMDi StefanoATuratoGCD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981573 Pt 18228269517597

 PubMed Web of Science ®Google Scholar

NavaSAmbrosinoNCliniENoninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trialAnn Intern Med199812897217289556465

 PubMed Web of Science ®Google Scholar

AnthonisenNRManfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164

 PubMed Web of Science ®Google Scholar

AnthonisenNRWrightECHodgkinJEPrognosis in chronic obstructive pulmonary-diseaseAm Rev Respir Dis1986133114203510578

 PubMed Web of Science ®Google Scholar

CazzolaMMacNeeWMartinezFJAmerican Thoracic SocietyEuropean Respiratory Society Task Force on outcomes of COPDOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951

 PubMed Web of Science ®Google Scholar

SiafakasNMVermeirePPrideNBOptimal assessment and management of chronic obstructive pulmonary disease (COPD)Eur Respir J199588139814207489808

 PubMed Web of Science ®Google Scholar

HoggJCPathophysiology of airflow limitation in chronic obstructive pulmonary diseaseLancet2004364943570972115325838

 PubMed Web of Science ®Google Scholar

MonsóERuizJRosellABacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brushAm J Respir Crit Care Med19951524 Pt 1131613207551388

 PubMed Web of Science ®Google Scholar

BrochardLManceboJWysockiMNoninvasive ventilation for acute exacerbations of chronic obstructive pulmonary diseaseN Engl J Med1995333138178227651472

 PubMed Web of Science ®Google Scholar

LandboCPrescottELangePVestboJAlmdalTPPrognostic value of nutritional status in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med199916061856186110588597

 PubMed Web of Science ®Google Scholar

RenzettiADMcClementJHLittBDThe Veterans Administration cooperative study of pulmonary function. 3. Mortality in relation to respiratory function in chronic obstructive pulmonary diseaseAm J Med19664111151295328350

 PubMed Web of Science ®Google Scholar

KeatingsVMCollinsPDScottDMBarnesPJDifferences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthmaAm J Respir Crit Care Med199615325305348564092

 PubMed Web of Science ®Google Scholar

Soler-CataluñaJJMartinez-GarcíaMARomán SanchezPRSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622

 PubMed Web of Science ®Google Scholar

MaltaisFSimardAASimardCJobinJDesgagnésPLeBlancPOxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPDAm J Respir Crit Care Med199615312882938542131

 PubMed Web of Science ®Google Scholar

SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117

 PubMed Web of Science ®Google Scholar

KuwanoKBoskenCHParéPDBaiTRWiggsBRHoggJCSmall airways dimensions in asthma and in chronic obstructive pulmonary diseaseAm Rev Respir Dis19931485122012258239157

 PubMed Web of Science ®Google Scholar

WilsonDORogersRMWrightECAnthonisenNRBody weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing TrialAm Rev Respir Dis19891396143514382658702

 PubMed Web of Science ®Google Scholar

BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619

 PubMed Web of Science ®Google Scholar

HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247

 PubMed Web of Science ®Google Scholar

SeneffMGWagnerDPWagnerRPZimmermanJEKnausWAHospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary diseaseJAMA199527423185218577500534

 PubMed Web of Science ®Google Scholar

TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213

 PubMed Web of Science ®Google Scholar

LacasseYWongEGuyattGHKingDCookDJGoldsteinRSMeta-analysis of respiratory rehabilitation in chronic obstructive pulmonary diseaseLancet19963489035111511198888163

 PubMed Web of Science ®Google Scholar

ScanlonPDConnettJEWallerLALung Health Study Research GroupSmoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health StudyAm J Respir Crit Care Med20001612 Pt 138139010673175

 PubMed Web of Science ®Google Scholar

DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669

 PubMed Web of Science ®Google Scholar

SaintSBentSVittinghoffEGradyDAntibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysisJAMA1995273129579607884956

 PubMed Web of Science ®Google Scholar

PaggiaroPLDahleRBakranIFrithLHollingworthKEfthimiouJMulticentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study GroupLancet199835191057737809519948

 PubMed Web of Science ®Google Scholar

BarnesPJChronic obstructive pulmonary diseaseN Engl J Med2000343426928010911010

 PubMed Web of Science ®Google Scholar

BarnesPJImmunology of asthma and chronic obstructive pulmonary diseaseNat Rev Immunol20088318319218274560

 PubMed Web of Science ®Google Scholar

CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702

 PubMed Web of Science ®Google Scholar

GanWQManSFSenthilselvanASinDDAssociation between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax200459757458015223864

 PubMed Web of Science ®Google Scholar

NiewoehnerDEErblandMLDeupreeRHEffect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study GroupN Engl J Med1999340251941194710379017

 PubMed Web of Science ®Google Scholar

VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med19961535153015358630597

 PubMed Web of Science ®Google Scholar

BarnesPJShapiroSDPauwelsRAChronic obstructive pulmonary disease: molecular and cellular mechanismsEur Respir J200322467268814582923

 PubMed Web of Science ®Google Scholar

BernardSLeBlancPWhittomFPeripheral muscle weakness in patients with chronic obstructive pulmonary-diseaseAm J Respir Crit Care Med199815826296349700144

 PubMed Web of Science ®Google Scholar

PapiABellettatoCMBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677

 PubMed Web of Science ®Google Scholar

CooperJDTrulockEPTriantafillouANBilateral pneumectomy (volume reduction) for chronic obstructive pulmonary diseaseJ Thorac Cardiovasc Surg19951091106116 discussion 116–1197815786

 PubMed Web of Science ®Google Scholar

BourbeauJJulienMMaltaisFChronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du QuébecReduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management interventionArch Intern Med2003163558559112622605

 PubMed Web of Science ®Google Scholar

SaettaMTuratoGMaestrelliPMappCEFabbriLMCellular and structural bases of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116361304130911371392

 PubMed Web of Science ®Google Scholar

CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942

 PubMed Web of Science ®Google Scholar

O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994

 PubMed Web of Science ®Google Scholar

Di FranciaMBarbierDMegeJLOrehekJTumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19941505 Pt 1145314557952575

 PubMed Web of Science ®Google Scholar

BestallJCPaulEAGarrodRGarnhamRJonesPWWedzichaJAUsefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax199954758158610377201

 PubMed Web of Science ®Google Scholar

PittaFTroostersTSpruitMAProbstVSDecramerMGosselinkRCharacteristics of physical activities in daily life in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171997297715665324

 PubMed Web of Science ®Google Scholar

ScholsAMBuurmanWAStaal van den BrekelAJDentenerMAWoutersEFEvidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary diseaseThorax19965188198248795671

 PubMed Web of Science ®Google Scholar

BuistASMcBurnieMAVollmerWMBOLD Collaborative Research GroupInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet2007370958974175017765523

 PubMed Web of Science ®Google Scholar

KeatingsVMJatakanonAWorsdellYMBarnesPJEffects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPDAm J Respir Crit Care Med199715525425489032192

 PubMed Web of Science ®Google Scholar

RahmanIAdcockIMOxidative stress and redox regulation of lung inflammation in COPDEur Respir J200628121924216816350

 PubMed Web of Science ®Google Scholar

PauwelsRALöfdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018

 PubMed Web of Science ®Google Scholar

O’DonnellDERevillSMWebbKADynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577077711549531

 PubMed Web of Science ®Google Scholar

SethiSMurphyTFBacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art reviewClin Microbiol Rev200114233636311292642

 PubMed Web of Science ®Google Scholar

ScholsAMSlangenJVolovicsLWoutersEFWeight loss is a reversible factor in the prognosis of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981576 Pt 1179117979620907

 PubMed Web of Science ®Google Scholar

WiggsBRBoskenCParéPDJamesAHoggJCA model of airway narrowing in asthma and in chronic obstructive pulmonary diseaseAm Rev Respir Dis19921456125112581595987

 PubMed Web of Science ®Google Scholar

WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806

 PubMed Web of Science ®Google Scholar

RiesALKaplanRMLimbergTMPrewittLMEffects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary diseaseAnn Intern Med1995122118238327741366

 PubMed Web of Science ®Google Scholar

PauwelsRARabeKFBurden and clinical features of chronic obstructive pulmonary disease (COPD)Lancet2004364943461362015313363

 PubMed Web of Science ®Google Scholar

DekhuijzenPNAbenKKDekkerIIncreased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19961543 Pt 18138168810624

 PubMed Web of Science ®Google Scholar

RepineJEBastALankhorstIThe Oxidative Stress Study GroupOxidative stress in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med199715623413579279209

 PubMed Web of Science ®Google Scholar

HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J200628352353216611654

 PubMed Web of Science ®Google Scholar

DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338

 PubMed Web of Science ®Google Scholar

CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001

 PubMed Web of Science ®Google Scholar

MurphyTFSethiSBacterial infection in chronic obstructive pulmonary-diseaseAm Rev Respir Dis19921464106710831416398

 PubMed Web of Science ®Google Scholar

NishimuraKIzumiTTsukinoMOgaTDyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPDChest200212151434144012006425

 PubMed Web of Science ®Google Scholar

ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526

 PubMed Web of Science ®Google Scholar

McSweenyAJGrantIHeatonRKAdamsKMTimmsRMLife quality of patients with chronic obstructive pulmonary-diseaseArch Intern Med198214234734787065785

 PubMed Web of Science ®Google Scholar

MenezesAMPerez-PadillaRJardimJRPLATINO TeamChronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence studyLancet200536695001875188116310554

 PubMed Web of Science ®Google Scholar

RahmanIMorrisonDDonaldsonKMacNeeWSystemic oxidative stress in asthma, COPD, and smokersAm J Respir Crit Care Med19961544 Pt 1105510608887607

 PubMed Web of Science ®Google Scholar

ScholsAMSoetersPBDingemansAMMostertRFrantzenPJWoutersEFPrevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitationAm Rev Respir Dis19931475115111568484624

 PubMed Web of Science ®Google Scholar

PatelISSeemungalTAWilksMLloyd-OwenSJDonaldsonGCWedzichaJARelationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbationsThorax200257975976412200518

 PubMed Web of Science ®Google Scholar

SethiSEvansNGrantBJMurphyTFNew strains of bacteria and exacerbations of chronic obstructive pulmonary diseaseN Engl J Med2002347746547112181400

 PubMed Web of Science ®Google Scholar

CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078

 PubMed Web of Science ®Google Scholar

O’DonnellDELamMWebbKAMeasurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981585 Pt 1155715659817708

 PubMed Web of Science ®Google Scholar

PlantPKOwenJLElliottMWEarly use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trialLancet200035592191931193510859037

 PubMed Web of Science ®Google Scholar

BhowmikASeemungalTASapsfordRJWedzichaJARelation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbationsThorax200055211412010639527

 PubMed Web of Science ®Google Scholar

AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045

 PubMed Web of Science ®Google Scholar

SinDDManSFWhy are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary diseaseCirculation2003107111514151912654609

 PubMed Web of Science ®Google Scholar

LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741216452599

 PubMed Web of Science ®Google Scholar

WeitzenblumEHirthCDucoloneAMirhomRRasaholinjanaharyJEhrhartMPrognostic value of pulmonary artery pressure in chronic obstructive pulmonary diseaseThorax198136107527587330793

 PubMed Web of Science ®Google Scholar

SeemungalTARDonaldsonGCBhowmikAJeffriesDJWedzichaJATime course and recovery of exacerbations in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200016151608161310806163

 PubMed Web of Science ®Google Scholar

AgustiAGNNogueraASauledaJSalaEPonsJBusquetsXSystemic effects of chronic obstructive pulmonary diseaseEur Respir J200321234736012608452

 PubMed Web of Science ®Google Scholar

KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333

 PubMed Web of Science ®Google Scholar

AltoseMDRedlineSDeitzCDEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260

 PubMed Web of Science ®Google Scholar

TraverGAClineMGBurrowsBPredictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up studyAm Rev Respir Dis19791196895902453709

 PubMed Web of Science ®Google Scholar

MarquisKDebigaréRLacasseYMidthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2002166680981312231489

 PubMed Web of Science ®Google Scholar

VestboJSørensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet199935391671819182310359405

 PubMed Web of Science ®Google Scholar

LambertRKWiggsBRKuwanoKHoggJCParéPDFunctional significance of increased airway smooth muscle in asthma and COPDJ Appl Physiol (1985)1993746277127818365980

 PubMed Web of Science ®Google Scholar

VinckenWvan NoordJAGreefhorstAPDutch/Belgian Tiotropium Study GroupImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363

 PubMed Web of Science ®Google Scholar

WagnerPDDantzkerDRDueckRVentilation-perfusion inequality in chronic obstructive pulmonary diseaseJ Clin Invest1977592203216833271

 PubMed Web of Science ®Google Scholar